John Garner

PLGA-PEG-NH2 from PolySciTech used in research on drug-delivery across the Blood-Brain-Barrier

Blog Post created by John Garner on Jun 18, 2019

In general uptake of medicinal molecules into the brain tissue from the blood-stream is very poor due to the blood-brain-barrier which generally prevents most molecules from getting into the brain. This naturally occurring phenomenon makes treatment of neural diseases very difficult. Recently, researchers at Universidade do Porto (Portugal) used PLGA-PEG-NH2 (AI058) from PolySciTech (www.polyscitech.com) used to create functional nanoparticles for controlling the crossing of the blood-brain-barrier. This research holds promise to improve efficacy of neural treatments for a variety of diseases. Read more: Maria João Bidarra Tavares Gomes “Modulation of drug efflux at the blood-brain barrier through targeted siRNA delivery via nanoparticles” PhD dissertation Universidade do Porto 2017. https://pdfs.semanticscholar.org/9a7e/057e12b64673536ad03b3560c4638941ee06.pdf

 

“Abstract (abbreviated): A BBB-targeted polymeric nanosystem was developed for delivery of siRNA against P-gp. Functionalized siRNA-loaded PLGA nanoparticles showed to be successful in silencing P-gp as a BBB efflux transporter and, consequently, in enhancing the blood-to-brain in vitro permeability of a P-gp substrate. Hence, drug efflux modulation at the BBB level was attained, bringing hope to CNS disorders treatments, since drugs could reach brain in higher and therapeutic concentrations. Additionally, being P-gp commonly over expressed at tumor cells, this polymeric system has the potential to be applied to cancer when properly functionalized to those cells.”

Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at www.bpcrconference.com

Outcomes